Cantor Fitzgerald Reiterates Overweight on Ocuphire Pharma, Maintains $17 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Ocuphire Pharma (NASDAQ:OCUP) and maintained a $17 price target.
August 14, 2023 | 12:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Ocuphire Pharma and maintained a $17 price target.
The reiteration of an Overweight rating by Cantor Fitzgerald indicates a positive outlook for Ocuphire Pharma. The maintained price target of $17 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100